DIGP - DigiPath, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0450
0.0000 (0.00%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.0450
Open0.0450
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0410 - 0.0450
52 Week Range0.0200 - 0.1650
Volume25,748
Avg. Volume83,712
Market Cap2.576M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-0.0350
Earnings DateMay 18, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Digipath Announces Results for Second Fiscal Quarter 2020, Revenues Grow 16% and 21% on a Year to Date Basis

    As an Essential Business, Digipath Remains Open to Serve Customers LAS VEGAS, NV, May 18, 2020 -- via NEWMEDIAWIRE – Digipath, Inc. (OTCQB: DIGP) (“DIGP” or the “Company”),.

  • GlobeNewswire

    Digipath to Import & Export Cannabis Genetics via Health Canada R&D License

    The import permits will enable the Company to import CBD and CBG seeds and grow them at three sites for the purpose of demonstrating that they are compliant, and to subsequently register them to Health Canada’s list of approved cultivars for worldwide export and distribution. It will also allow the Company to import unique Genetics expressing CBG and CBN. “This permission essentially gives our Company the ability to interact and engage with a global network of companies in the international cannabis economy and to greatly accelerate our penetration into new markets,” said Kyle Remenda, CEO, Digipath, Inc. “The company will be growing a variety of approved cultivars under the existing Research and Development license, with an ultimate goal of registering the genetics within the legal framework of Health Canada and to sell them to hemp producers, not only outdoor cannabis cultivations.”

  • Cannabis Businesses Essential in Stressful Times -- SECFilings.com
    Newsfile

    Cannabis Businesses Essential in Stressful Times -- SECFilings.com

    Redondo Beach, California--(Newsfile Corp. - April 13, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing the robust level of cannabis sales during the ongoing pandemic response and the role of companies like Digipath, Inc. (OTCQB: DIGP) in supporting the industry while consumer brands find their footing.If you've been following the cannabis industry, and particularly the investment ...

  • GlobeNewswire

    Digipath Obtains Health Canada R&D License for Cannabis Strain Development and Sales

    License Comes Via Recent Acquisition of VSSL Enterprises Ltd. VSSL’s management team, including Kyle Remenda and Dr. Philippe Henry have joined Digipath’s management team as CEO and Chief Technology Officer, respectively.

  • GlobeNewswire

    Digipath Completes Acquisition of VSSL Enterprises Ltd.

    VSSL, located in Kelowna, B.C., is a provider of agritech consulting solutions in the areas of cannabis genetics, tissue culture, cultivation, analytical testing and predictive tools. The two co-founders of VSSL, Kyle Remenda and Dr. Philippe Henry, joined Digipath’s executive team in September 2019, and bring a wealth of scientific and practical expertise and industry relationships to the Company.

  • GlobeNewswire

    The Emerging Markets Report: A Record Rise in Revenue

    To this end, Tuesday’s revenue news from cannabis testing and technology company Digipath (DIGP) should turn heads. Digipath is well-established as a market leader in the mandatory Nevada testing industry. Digipath, Inc., supports the cannabis industry’s best practices for reliable testing, data acquisition, formulations, and new canna-tech to the cannabis industry.

  • GlobeNewswire

    Digipath Announces Results for the Fiscal First Quarter 2020, Revenues Grow 26%

    Gross Profit Also Increases 150% Year Over Year LAS VEGAS, NV, Feb. 18, 2020 -- via NEWMEDIAWIRE -- Digipath, Inc. (OTCQB: DIGP) (“DIGP” or the “Company”), a.

  • GlobeNewswire

    Emerging Markets Report:  At the Intersection of Cannabis and Commerce

    In fact, a recent Forbes article cites a report that predicts legal cannabis sales will grow to nearly $30 billion by 2025. As one of the leading cannabis testing labs Digipath is well-positioned at the intersection of cannabis and commerce, a regulatory necessity to legal sale. Want to sell cannabis products most anywhere in the country?

  • GlobeNewswire

    Digipath Processes Record Number of Samples, Plans Expansion

    LAS VEGAS, NV, Feb. 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Digipath, Inc. (DIGP), is pleased to announce a 50% increase in cannabis sample processing for January of 2020 versus the same period in 2019. To meet growing demand, Digipath has purchased a SCIEX Triple Quad 6500+ LC-MS/MS System which is widely considered to be a state-of-the-art diagnostic instrument featuring multi-component IonDrive Technology including the IonDrive High Energy Detector+ that pushes the boundaries of LC-MS/MS quantitation farther than ever before. Additionally, Digipath is in the process of expanding its laboratory space.

  • GlobeNewswire

    Digipath to Acquire Cannabis Technology Firm VSSL Enterprises Ltd.

    LAS VEGAS, NV, Sept. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Digipath, Inc. (DIGP), is pleased to announce it has entered into a binding letter of intent for the acquisition of VSSL Enterprises Ltd. (“VSSL”), a British Columbia based cannabis genomics, plant sciences and consulting firm. The acquisition is expected to provide Digipath with a wealth of cannabis data, technology and intellectual property, including in excess of a thousand hemp and cannabis genotypes. The letter of intent provides for the acquisition of 100% of VSSL’s outstanding shares of capital stock for consideration consisting of six million shares of Digipath common stock and a cash payment of $200,000, and is subject to the execution of definitive agreements.

  • GlobeNewswire

    GroSciences Initiates Beta-testing of Tru-Hemp ID In North Carolina and Vermont

    BOULDER, CO, Aug. 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Digipath, Inc. (DIGP), a leading independent testing laboratory, data analytics and formulation firm focused on the developing cannabis and hemp markets, is pleased to announce that GroSciences, its wholly owned subsidiary, has successfully completed beta-testing of its “Tru-Hemp ID” kit. Under the 2018 Farm Bill that legalized hemp cultivation, hemp is defined as having less than 0.3% delta-9-THC by dry weight.  As a result, compliance with the 2018 Farm Bill is usually determined by analyzing the THC content of a particular plant sample.  Tru-Hemp ID offers a simpler method for determining the strain of a particular plant in the form of a genetic test.  A full analysis of all data collected thus far using the Tru-Hemp ID kit that correlates the genetic outcome of samples with their actual THC content will be forthcoming.

  • Digipath's GroSciences Moving Forward with Further Testing for its Patent Pending All-Natural, Plant-Derived Pesticide
    PR Newswire

    Digipath's GroSciences Moving Forward with Further Testing for its Patent Pending All-Natural, Plant-Derived Pesticide

    BOULDER, Colo., Aug. 14, 2019 /PRNewswire/ -- Digipath, Inc. (DIGP), a service-oriented independent testing laboratory, data analytics and formulation firm focused on the developing cannabis and hemp markets, is pleased to announce that its GroSciences division has successfully completed preliminary validation testing on its patent pending all-natural, plant-derived pesticide, TERPO+ Broadspectrum. The product could potentially serve an enormous market by protecting cannabis plants against colonization by microorganisms. The testing has also shown that TERPO+ Broadspectrum acts as a treatment for the elimination of microbial bioburden on cannabis and hemp flowers.

  • Digipath Announces Results for the Fiscal Third Quarter 2019, Revenues Grow 25% Year Over Year
    PR Newswire

    Digipath Announces Results for the Fiscal Third Quarter 2019, Revenues Grow 25% Year Over Year

    Revenue Growth Comes as New Potential Revenue Lines Move into Beta Testing LAS VEGAS , Aug. 13, 2019 /PRNewswire/ --  Digipath, Inc.   (OTCQB: DIGP) ("DIGP" or the "Company"), a service-oriented ...

  • PR Newswire

    Digipath Reports Significant Progress on GroSciences' Tru-Hemp ID Kit

    LAS VEGAS, July 29, 2019 /PRNewswire/ -- Digipath, Inc. (DIGP) ("DIGP" or the "Company"), a service-oriented independent testing laboratory, data analytics and formulation firm focused on the developing cannabis and hemp markets, is pleased to announce that the Company's GroSciences subsidiary has made significant progress in developing its Tru-Hemp ID project, with commercial availability targeted for late 2019/early 2020. GroSciences is Digipath's wholly owned subsidiary which combines years of testing data and proprietary research to create "The Science to Succeed" for clients wanting expert guidance on formulations, identification, and more. As previously reported, Digipath, via GroSciences, has been developing a field testing kit for hemp, cannabis and other related products with a myriad of applications from law enforcement to growers.

  • ACCESSWIRE

    Digipath, Inc. Joins The Stock Day Podcast to Discuss their Expansion into Columbia

    PHOENIX, AZ / ACCESSWIRE / July 18, 2019 / The Stock Day Podcast welcomed Digipath, Inc. (DIGP) (“the Company”), a service-oriented independent testing laboratory, data analytics, and formulation firm focused on the developing cannabis and hemp markets. CEO and Founder, Todd Denkin, joined Stock Day host Everett Jolly. Jolly began the interview by asking about the Company’s recent announcement of a field test for cannabis versus hemp identification for law enforcement.

  • Digipath CEO Todd Denkin Interviewed by CEO Roadshow
    PR Newswire

    Digipath CEO Todd Denkin Interviewed by CEO Roadshow

    LAS VEGAS, July 16, 2019 /PRNewswire/ -- Digipath, Inc. (DIGP) ("DIGP" or the "Company"), a service-oriented independent testing laboratory, data analytics and formulation firm focused on the developing cannabis and hemp markets, is pleased to announce that Company CEO Todd Denkin was recently interviewed by CEO Roadshow with veteran journalist Mike Elliott. In this interview, Denkin discusses the Company's recent provisional patent applications involving terpene technology. "It's always a pleasure to sit down with Mr. Elliott, who is a true professional with a significant following," stated Todd Denkin, CEO, Digipath Inc. "In this interview we covered some of the more exciting things happening for Digipath and its shareholders.

  • Digipath Labs Awarded Five New Emerald Badges™ for Excellence in Cannabis Testing By Emerald Scientific
    PR Newswire

    Digipath Labs Awarded Five New Emerald Badges™ for Excellence in Cannabis Testing By Emerald Scientific

    An Emerald Badge™ is awarded to labs that perform within a specific tolerance in each proficiency test category, with criteria established by the ISO accredited PT manufacturer with input from the Emerald Test Advisory Panel. Labs that receive a Badge are recognized for their capabilities in comparison to their peers within a given series.  In addition, the Emerald Badge affirms a lab's ability to meet regulatory requirements for licensure, and  Emerald Test ILC/PT participation satisfies ISO/IEC 17043 accreditation requirements for external proficiency testing.

  • Digipath's Dr. Cindy Orser Featured in Forbes Article on Cannabis Strains/Cultivars
    PR Newswire

    Digipath's Dr. Cindy Orser Featured in Forbes Article on Cannabis Strains/Cultivars

    The article, written by Forbes contributor Andre Bourque, addresses the messy nomenclature of the current cannabis market wherein an imprecise system of non-scientific names is used to identify and sell cannabis strains, or more accurately cannabis cultivars. Mr. Bourque refers to Dr. Orser and her colleague Dr. Philippe Henry's assertion that "the cannabis consumer patient often times has no real idea of the composition, consistency or comparability of the cannabis product that they purchase," in their previous peer-reviewed publication "Making Sense of Cannabis Strains through Chemometrics," in Cannabis Science & Technology.

  • Digipath Benefits from Record Cannabis Sales in Nevada
    PR Newswire

    Digipath Benefits from Record Cannabis Sales in Nevada

    This corresponds with the increased demand Digipath is experiencing for its governmentally required cannabis testing services in Nevada. In March alone, the State of Nevada reported record cannabis sales of just under $60 million. Recreational sales were $53.6 million, up $11.1 million from February, while medicinal sales were off by $800,000.